Exelixis

Natera

Corcept Therapeutics

Intra-Cellular Therapies

ACADIA Pharma

Incyte

Catalyst Pharmaceuticals

Gilead Sciences

Neurocrine Biosciences

United Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

FBT tracks an equal-weighted index of US biotechnology stocks.

VanEck Vectors Biotech ETF

Principal Healthcare Innovators Index ETF

iShares Nasdaq Biotechnology ETF

ImmunityBio

Novavax

Ocugen, Inc.

SPDR S&P Biotech ETF

Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.

Virtus LifeSci Biotech Products ETF

Loncar Cancer Immunotherapy ETF

Direxion Daily Healthcare Bull 3x Shares

Fidelity MSCI Health Care ETF

First Trust Nasdaq Pharmaceuticals ETF 

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Healthcare Investors 

abrdn Life Sciences Investors 

Defiance Nasdaq Junior Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare ETF

John Hancock Multifactor Healthcare ETF

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Global X Longevity Thematic ETF

Invesco Dynamic Biotechnology & Genome ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

ProShares UltraShort Health Care

ProShares Ultra Health Care

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

Pacer BioThreat ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.

Biotech Innovations Remain At Forefront

Virtus LifeSci Biotech Clinical Trials ETF

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.

Moving Beyond COVID In Biopharma

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

ARK Genomic Revolution Multi-Sector ETF

BioNTech SE

ALPS Medical Breakthroughs ETF

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

Global X Telemedicine & Digital Health ETF

WisdomTree U.S. SmallCap Earnings Fund

iShares Global Clean Energy ETF

Invesco KBW Bank ETF

Proshares Online Retail ETF

Invesco Nasdaq 100 ETF

Industrial Select Sector SPDR Fund

Two ETF experts share their market outlook and top picks for 2021.

ETF Market Outlook & Picks for 2021

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion Pharmaceuticals (NASDAQ: ALXN). U.K.-based AstraZeneca, which is one of the prime players in the COVID-19 vaccine race, is valuing Alexion at $175 per share in this year's biggest pharmaceuticals takeover.

3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover

First Trust NASDAQ Global Auto Index Fund

US Global Jets ETF

SPDR S&P Regional Banking ETF

Invesco Dynamic Leisure and Entertainment ETF

SPDR S&P Oil & Gas Equipment & Services ETF

Energy Select Sector SPDR Fund

The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.

ETF Sectors to Bet on Positive Vaccine News

As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds, which are already garnering interest as 2020 winds down.

Can't Get Enough Biotech Exposure in Your Portfolio?

Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoon, on track for its biggest daily gain in nearly three weeks.

Biotech ETFs at multi-week highs, extending winning streak

Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biotechnology Index Fund were all up 1.4% at midday, dwarfing the 0.4% rise for the S&P 500.

Biotech ETFs at two-week highs on upbeat vaccine news

Pfizer

Regeneron Pharmaceuticals

West Pharmaceutical Services

As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions. The post 7 Biotech Stocks To Buy For Profit From The Vaccine Crunch appeared first on InvestorPlace.

7 Biotech Stocks To Buy For Profit From The Vaccine Crunch

Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.

Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies

Teladoc

Not all healthcare ETFs are the same and as this group of three proves, that can be a positive for savvy investors.
The post 3 Healthcare ETFs to Buy for Health and Safety appeared first on InvestorPlace.

3 Healthcare ETFs to Buy for Health and Safety

Healthcare is one of the most politically sensitive sectors and that sensitivity is on full display in recent weeks with biotechnology ETFs, including the First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT). Recent weakness among FBT and other biotech ETFs isn’t necessarily surprising with Election Day looming.

Encouraging Election Year History for this Biotech ETF

Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.

How Will Biotech ETFs React to Vaccine Makers' Safety Pledge?

Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't ignore these funds for too long.

Election History Says Buy Biotech Dip

AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.

Biotech ETFs to Shine Bright on Coronavirus Vaccine Progress

These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.

Post-Pandemic Stars Could Align For This Biotech ETF

Biotech ETFs are popular and delivering for investors, but not all of these funds need the Covid-19 pandemic to soar.

7 Biotech ETFs to Buy Now For Covid-19 And Beyond

ARK Web x.0 ETF

iShares MSCI USA ESG Optimized ETF

Vanguard ESG US Stock ETF

First Trust Dow Jones Internet Index Fund

O'Shares Global Internet Giants ETF

Invesco NASDAQ Internet ETF

Xtrackers MSCI USA ESG Leaders Equity ETF

Let's check out some ETF areas that will remain solid investment picks even as the coronavirus cases show a sharp spike.

Red Hot ETF Areas Amid the Coronavirus Crisis

Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.

Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain

The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.

News for First Trust NYSE Arca Biotechnology Index Fund ETF (FBT)